Department of Hepato-Biliary-Pancreatic Surgey, Navy General Hospital of Chinese People's Liberation Army, Beijing 100048, China.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital & Institute, Beijing 100142, China.
World J Gastroenterol. 2018 Jun 28;24(24):2596-2604. doi: 10.3748/wjg.v24.i24.2596.
To determine a panel of serum microRNAs (miRNAs) that could be used as novel biomarkers for diagnosis of hepatocellular carcinoma (HCC).
We initially screened 9 out of 754 serum miRNAs by TaqMan Low Density Array in two pooled samples respectively from 35 HCC and 35 normal controls, and then validated individually by RT-qPCR in another 114 patients and 114 controls arranged in two phases. The changes of the selected miRNAs after operation and their prognostic value were examined.
miR-375, miR-10a, miR-122 and miR-423 were found to be significantly higher in HCC than in controls ( < 0.0001), and the area under the receiver-operating-characteristic curve for the 4-miRNA panel was 0.995 (95%CI: 0.985-1). All the four miRNAs were significantly reduced after surgical removal of the tumors ( < 0.0001), while still higher than normal controls (at least < 0.05).
The four serum miRNAs (miR-375, miR-10a, miR-122 and miR-423) could potentially serve as novel biomarkers for the diagnostic and prognostic of HCC.
确定一组可作为肝细胞癌(HCC)诊断新型生物标志物的血清 microRNAs(miRNAs)。
我们最初通过 TaqMan 低密度阵列在两个分别来自 35 例 HCC 和 35 例正常对照的混合样本中筛选了 754 个血清 miRNAs 中的 9 个,然后在另外的 114 例患者和 114 例对照中分别通过 RT-qPCR 进行了单独验证,这些患者和对照分为两个阶段。检测了所选 miRNA 术后的变化及其预后价值。
miR-375、miR-10a、miR-122 和 miR-423 在 HCC 中明显高于对照组(<0.0001),四 miRNA 组合的受试者工作特征曲线下面积为 0.995(95%CI:0.985-1)。所有四个 miRNA 在肿瘤切除术后均显著降低(<0.0001),但仍高于正常对照组(至少 <0.05)。
四种血清 miRNAs(miR-375、miR-10a、miR-122 和 miR-423)可能可作为 HCC 诊断和预后的新型生物标志物。